- Stocks
- Healthcare
- NYSE: BSX

Price (delayed)

$42.33

Market cap

$60.6B

P/E Ratio

74.26

Dividend/share

N/A

EPS

$0.57

Enterprise value

$69.3B

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology,

The EPS has soared by 54% YoY and by 10% from the previous quarter

Boston Scientific's net income has surged by 52% YoY and by 9% QoQ

BSX's quick ratio is down by 48% year-on-year but it is up by 10% since the previous quarter

The P/E is 16% below the 5-year quarterly average of 88.9 but 11% above the last 4 quarters average of 67.1

What are the main financial stats of BSX

Market
Valuations
Earnings

Shares outstanding

1.43B

Market cap

$60.6B

Enterprise value

$69.3B

Price to earnings (P/E)

74.26

Price to book (P/B)

3.51

Price to sales (P/S)

4.91

EV/EBIT

42.8

EV/EBITDA

25.3

EV/Sales

5.62

Revenue

$12.33B

EBIT

$1.62B

EBITDA

$2.74B

Free cash flow

$684M

Per share
Balance sheet
Liquidity

EPS

$0.57

Free cash flow per share

$0.48

Book value per share

$12.07

Revenue per share

$8.62

TBVPS

$9.06

Total assets

$32.19B

Total liabilities

$14.94B

Debt

$8.97B

Equity

$17.25B

Working capital

$1.2B

Debt to equity

0.52

Current ratio

1.31

Quick ratio

0.56

Net debt/EBITDA

3.17

Margins
Efficiency
Dividend

EBITDA margin

22.2%

Gross margin

68.9%

Net margin

7.2%

Operating margin

11.9%

Return on assets

2.6%

Return on equity

4.9%

Return on invested capital

9.4%

Return on capital employed

5.7%

Return on sales

13.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Boston Scientific stock price performed over time

Intraday

1.36%

1 week

3.4%

1 month

14.78%

1 year

-3.95%

YTD

-0.35%

QTD

13.58%

How have Boston Scientific's revenue and profit performed over time

Revenue

$12.33B

Gross profit

$8.49B

Operating income

$1.46B

Net income

$883M

Gross margin

68.9%

Net margin

7.2%

BSX's operating margin has surged by 183% year-on-year and by 11% since the previous quarter

Boston Scientific's net income has surged by 52% YoY and by 9% QoQ

Boston Scientific's net margin has increased by 38% YoY and by 7% QoQ

Boston Scientific's gross profit has increased by 13% YoY

What is Boston Scientific's growth rate over time

What is Boston Scientific stock price valuation

P/E

74.26

P/B

3.51

P/S

4.91

EV/EBIT

42.8

EV/EBITDA

25.3

EV/Sales

5.62

The EPS has soared by 54% YoY and by 10% from the previous quarter

The P/E is 16% below the 5-year quarterly average of 88.9 but 11% above the last 4 quarters average of 67.1

The stock's price to book (P/B) is 22% less than its 5-year quarterly average of 4.5 and 2.5% less than its last 4 quarters average of 3.6

The equity has grown by 8% YoY and by 3.1% from the previous quarter

The revenue has increased by 10% YoY

How efficient is Boston Scientific business performance

BSX's ROIC has soared by 84% YoY and by 11% from the previous quarter

The ROS has soared by 62% YoY and by 10% from the previous quarter

The return on assets has surged by 53% year-on-year and by 8% since the previous quarter

The return on equity has increased by 44% year-on-year and by 7% since the previous quarter

What is BSX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BSX.

How did Boston Scientific financials performed over time

Boston Scientific's total assets is 115% more than its total liabilities

BSX's quick ratio is down by 48% year-on-year but it is up by 10% since the previous quarter

BSX's current ratio is down by 21% year-on-year but it is up by 11% since the previous quarter

Boston Scientific's debt is 48% lower than its equity

Boston Scientific's debt to equity has decreased by 9% YoY and by 7% from the previous quarter

The equity has grown by 8% YoY and by 3.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.